Yuhan (YUHNF) Cyclically Adjusted PS Ratio: (As of Jul. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Yuhan Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Yuhan  (OTCPK:YUHNF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Yuhan Cyclically Adjusted PS Ratio Related Terms


Yuhan Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Yuhan's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yuhan Cyclically Adjusted PS Ratio Chart

Yuhan Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.39 2.94 3.41 5.51 4.83

Yuhan Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.92 4.62 5.19 4.83 3.99

YUHNF vs ZTS: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Yuhan's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yuhan Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Yuhan's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Yuhan's Cyclically Adjusted PS Ratio falls into.



Yuhan Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Yuhan's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Yuhan's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=4.731/125.2360*125.2360
=4.731

Current CPI (Mar. 2026) = 125.2360.

Yuhan Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 3.764 100.791 4.677
201609 4.302 101.461 5.310
201612 4.815 101.561 5.937
201703 4.086 102.851 4.975
201706 3.786 102.611 4.621
201709 4.499 103.491 5.444
201712 5.631 102.991 6.847
201803 4.247 104.101 5.109
201806 4.682 104.130 5.631
201809 4.184 105.651 4.960
201812 5.990 104.351 7.189
201903 4.225 104.491 5.064
201906 0.800 104.881 0.955
201909 0.843 105.200 1.004
201912 0.737 105.121 0.878
202003 0.646 105.354 0.768
202006 4.328 105.112 5.157
202009 4.585 106.198 5.407
202012 5.322 105.765 6.302
202103 4.217 107.357 4.919
202106 4.852 107.579 5.648
202109 3.792 108.759 4.366
202112 4.992 109.676 5.700
202203 4.253 111.848 4.762
202206 5.021 114.072 5.512
202209 4.097 114.715 4.473
202212 3.885 115.179 4.224
202303 4.301 116.507 4.623
202306 4.865 117.182 5.199
202309 4.594 118.964 4.836
202312 5.269 118.837 5.553
202403 4.439 120.123 4.628
202406 5.114 120.007 5.337
202409 5.999 120.861 6.216
202412 4.590 121.135 4.745
202503 4.506 122.590 4.603
202506 5.656 122.611 5.777
202509 5.535 123.402 5.617
202512 4.984 123.939 5.036
202603 4.731 125.236 4.731

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Yuhan Business Description

Other Exchanges 000105:Korea000100:Korea
Address 74 Noryangjin-ro, Daebang-dong, Dongjak-gu, Seoul, KOR
Yuhan Corp is a pharmaceutical company. The core business of the company is classified as primary and specialty care, dietary supplements, household and animal care, and contract manufacturing of active pharmaceutical ingredients. The company offers one-stop custom synthesis services from research and development to commercial production of active pharmaceutical products (APIs) and intermediates for the following disease treatments: antivirals (HCV and HIV), antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds for international markets.